EUVIMEDEUVIMED entdecken
Crossref

Novel Macrocyclic NLRP3 Inhibitors

Stefanie Mesch iD, Jonathan Shannon, David Miller, Angus MacLeod, Léa Bouché iD, Heather J Johnston, Kim Matthews, Axel Paehler, Stuart Best, Wolfgang Guba iD, Thomas Alanine, Reena Halai und 16 weitere

Journal of Medicinal Chemistry · 12.12.2024 · 67 (23) · 20911-20932

DOI: 10.1021/acs.jmedchem.4c01376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 25.11.2024. Verfasst von Stefanie Mesch und 27 weiteren Autor:innen. Beteiligte Einrichtung: F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel CH-4070, Switzerland. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aberrant activation of NLRP3 due to persistent tissue damage, misfolded proteins or crystal deposits has been linked to multiple chronic inflammatory disorders such as cryopyrin-associated periodic syndrome (CAPS), neurodegenerative diseases, gouty arthritis, and numerous others. Hence, there has been an increasing interest in NLRP3 inhibitors as therapeutics. A first generation of NLRP3 inhibitors bearing a sulfonylurea core such as MCC950 (developed by Pfizer) were discovered by phenotypic screening, however their mode of action was only elucidated later. Based on MCC950, second-generation inhibitors were developed, aiming to overcome some liabilities such as moderate potency and drug induced liver injury. During the optimization of these (second-generation) inhibitors, conformational studies led to the design of novel macrocycles. Here we report the discovery and optimization of this class of NLRP3 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NLR Family, Pyrin Domain-Containing 3 ProteinHumansAnimalsStructure-Activity RelationshipMacrocyclic CompoundsSulfonesSulfonamidesMiceFuransIndenes

Substanzen

NLR Family, Pyrin Domain-Containing 3 ProteinMacrocyclic CompoundsNLRP3 protein, humanSulfonesSulfonamidesN-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamideFuransIndenes

Autor:innen und Institutionen

  • F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel CH-4070, Switzerland.
  • Sygnature Discovery, BioCity, Pennyfoot Street, Nottingham NG1 1GF, U.K.
  • Inflazome Ltd., 6 Falcon Way, Shire Park, Welwyn Garden City AL7 1TW, U.K.

ORCID-Profile: Stefanie Mesch, Léa Bouché, Wolfgang Guba, Jokin Carrillo, Alan G Hendrick, Georg Jaeschke

Zitieren

APA

Mesch, S., Shannon, J., Miller, D., MacLeod, A., Bouché, L., Johnston, H. J., Matthews, K., Paehler, A., Best, S., Guba, W., Alanine, T., Halai, R., Charge, L., Garside, S., Thom, S., Incerti-Pradillos, C., McPherson, C., Carrillo, J., St-Gallay, S., …, & Cooper, M. A. (2024). Novel Macrocyclic NLRP3 Inhibitors. Journal of Medicinal Chemistry, 67(23), 20911-20932. https://doi.org/10.1021/acs.jmedchem.4c01376

Vancouver

Mesch S, Shannon J, Miller D, MacLeod A, Bouché L, Johnston HJ, et al. Novel Macrocyclic NLRP3 Inhibitors. Journal of Medicinal Chemistry. 2024;67(23):20911-20932. doi:10.1021/acs.jmedchem.4c01376

BibTeX
@article{Mesch2024,
  author = {Mesch, Stefanie and Shannon, Jonathan and Miller, David and MacLeod, Angus and Bouché, Léa and Johnston, Heather J and Matthews, Kim and Paehler, Axel and Best, Stuart and Guba, Wolfgang and Alanine, Thomas and Halai, Reena and Charge, Lorna and Garside, Samantha and Thom, Stephen and Incerti-Pradillos, Celia and McPherson, Christopher and Carrillo, Jokin and St-Gallay, Steve and Rigo, Pierre and Schlicht, Sonja and Hendrick, Alan G and Lerner, Christian and Piali, Luca and Blaising, Julie and Mracsko, Eva Z and Jaeschke, Georg and Cooper, Matthew A},
  title = {Novel Macrocyclic NLRP3 Inhibitors},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {23},
  pages = {20911--20932},
  doi = {10.1021/acs.jmedchem.4c01376}
}
Kostenlos starten →